肺癌EGFR-TKIs浓度测定方法研究进展  

Progress in concentration determination of EGFR-TKIs in lung cancer

作　　者：杨培丹 梁平[1] 郭霞[1] 尹金妥 侯娟[1] 冯锐[1] 刘江[1] YANG Pei-dan;LIANG Ping;GUO Xia;YIN Jin-tuo;HOU Juan;FENG Rui;LIU Jiang(The Fourth Hospital of Hebei Medical University,Shijiazhuang 050011,China)

机构地区：[1]河北医科大学第四医院,石家庄050011

出　　处：《药物分析杂志》2023年第3期359-365,共7页Chinese Journal of Pharmaceutical Analysis

基　　金：河北省自然科学基金资助项目(H2021206441)。

摘　　要：表皮生长因子酪氨酸激酶抑制剂(epidermal growth factor receptor-tyrosine kinase inhibitor, EGFR-TKI)已广泛用于肺癌靶向治疗,监测药物浓度对指导临床用药具有广泛意义。通过数据库检索肺癌靶向药物血、尿、脑脊液浓度测定的方法,对目前国内外生物样品药品检测方法进行总结分析,发现当前国内外对肺癌靶向药物测定多为血药浓度监测,鲜有对尿、脑脊液中的药物监测,其中药物浓度监测的方法主要为HPLC-MS/MS,分析条件各有差异。目前国内相关研究较为缺乏,本文可为研究人员在开发量化方法和选择检测器时提供一些思路。EGFR-TKIs(epidermal growth factor receptor-tyrosine kinase inhibitor)has been widely used in lung cancer targeted therapy.Monitoring drug concentration has extensive significance for guiding clinical medica-tion.Through the database search for the methods of determining lung cancer targeted drugs concentration in blood,urine,and cerebrospinal fluid,current domestic and foreign biological sample drug detection methods are summarized and analyzed.Present domestic and foreign lung cancer targeted drug measurement saremainly blood drug concentration monitoring.Drug concentration measurementsin the urine or cerebrospinal fluid are rare.HPLC-MS/MS method is mainly used in drug concentration monitoring and the analysis conditions are different.Besides,related research in China is insufficient.This paper can provide ideas for researchers before developing quantitative methods and selecting detectors.

关 键 词：非小细胞肺癌 表皮生长因子受体酪氨酸激酶抑制剂 血药浓度 尿药浓度 脑脊液浓度 高效液相色谱-串联质谱 

分 类 号：R917[医药卫生—药物分析学]